Is TNGX or VTRS more profitable?

Viatris has a net margin of -2.04% compared to Tango Therapeutics' net margin of -151.15%. Viatris' return on equity of 19.04% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics -151.15% -41.54% -33.44% Viatris -2.04% 19.04% 7.62%

Does the media prefer TNGX or VTRS?

In the previous week, Viatris had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 3 mentions for Viatris and 2 mentions for Tango Therapeutics. Viatris' average media sentiment score of 0.48 beat Tango Therapeutics' score of 0.34 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TNGX or GMAB?

In the previous week, Genmab A/S had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 3 mentions for Genmab A/S and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.34 beat Genmab A/S's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TNGX or ASND?

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than Tango Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 2 mentions for Tango Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.16 beat Tango Therapeutics' score of 0.34 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BBIO or TNGX?

In the previous week, BridgeBio Pharma had 11 more articles in the media than Tango Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 2 mentions for Tango Therapeutics. BridgeBio Pharma's average media sentiment score of 0.86 beat Tango Therapeutics' score of 0.34 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AXSM or TNGX?

In the previous week, Axsome Therapeutics had 7 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 2 mentions for Tango Therapeutics. Axsome Therapeutics' average media sentiment score of 1.01 beat Tango Therapeutics' score of 0.34 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tango Therapeutics (TNGX) Competitors

$28.39 -0.11 (-0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$28.40 +0.01 (+0.04%)

As of 07:51 PM Eastern

Compare

TNGX vs. VTRS, GMAB, ASND, BBIO, and AXSM

Should you buy Tango Therapeutics stock or one of its competitors? MarketBeat compares Tango Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tango Therapeutics include Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Tango Therapeutics compare to Viatris?

Tango Therapeutics (NASDAQ:TNGX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Viatris has a net margin of -2.04% compared to Tango Therapeutics' net margin of -151.15%. Viatris' return on equity of 19.04% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Viatris	-2.04%	19.04%	7.62%

Tango Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Viatris has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tango Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	65.83	-$101.59M	-$0.83	N/A
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A

Tango Therapeutics presently has a consensus price target of $38.42, indicating a potential upside of 35.32%. Viatris has a consensus price target of $17.50, indicating a potential upside of 11.11%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tango Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Viatris had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 3 mentions for Viatris and 2 mentions for Tango Therapeutics. Viatris' average media sentiment score of 0.48 beat Tango Therapeutics' score of 0.34 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tango Therapeutics and Viatris tied by winning 8 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Genmab A/S?

Tango Therapeutics (NASDAQ:TNGX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Genmab A/S has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	65.83	-$101.59M	-$0.83	N/A
Genmab A/S	$3.72B	4.35	$963M	$1.32	19.65

Genmab A/S has a net margin of 21.05% compared to Tango Therapeutics' net margin of -151.15%. Genmab A/S's return on equity of 15.34% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Genmab A/S	21.05%	15.34%	8.94%

Tango Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Tango Therapeutics presently has a consensus target price of $38.42, indicating a potential upside of 35.32%. Genmab A/S has a consensus target price of $37.93, indicating a potential upside of 46.22%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts clearly believe Genmab A/S is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Genmab A/S had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 3 mentions for Genmab A/S and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.34 beat Genmab A/S's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Genmab A/S beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Tango Therapeutics (NASDAQ:TNGX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than Tango Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 2 mentions for Tango Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.16 beat Tango Therapeutics' score of 0.34 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Tango Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tango Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Tango Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	65.83	-$101.59M	-$0.83	N/A
Ascendis Pharma A/S	$865.78M	17.19	-$258M	$8.67	27.52

Tango Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Tango Therapeutics presently has a consensus price target of $38.42, suggesting a potential upside of 35.32%. Ascendis Pharma A/S has a consensus price target of $295.39, suggesting a potential upside of 23.81%. Given Tango Therapeutics' higher possible upside, equities analysts plainly believe Tango Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Ascendis Pharma A/S has a net margin of 57.87% compared to Tango Therapeutics' net margin of -151.15%. Ascendis Pharma A/S's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Summary

Ascendis Pharma A/S beats Tango Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

BridgeBio Pharma has a net margin of -124.42% compared to Tango Therapeutics' net margin of -151.15%. BridgeBio Pharma's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

BridgeBio Pharma presently has a consensus target price of $91.05, indicating a potential upside of 32.66%. Tango Therapeutics has a consensus target price of $38.42, indicating a potential upside of 35.32%. Given Tango Therapeutics' higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, BridgeBio Pharma had 11 more articles in the media than Tango Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 2 mentions for Tango Therapeutics. BridgeBio Pharma's average media sentiment score of 0.86 beat Tango Therapeutics' score of 0.34 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Tango Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Tango Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$579.96M	23.18	-$724.93M	-$3.74	N/A
Tango Therapeutics	$62.38M	65.83	-$101.59M	-$0.83	N/A

99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

BridgeBio Pharma beats Tango Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Axsome Therapeutics presently has a consensus target price of $258.95, indicating a potential upside of 7.02%. Tango Therapeutics has a consensus target price of $38.42, indicating a potential upside of 35.32%. Given Tango Therapeutics' higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Axsome Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tango Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$708.24M	17.58	-$183.17M	-$3.73	N/A
Tango Therapeutics	$62.38M	65.83	-$101.59M	-$0.83	N/A

Axsome Therapeutics has a net margin of -26.59% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

In the previous week, Axsome Therapeutics had 7 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 2 mentions for Tango Therapeutics. Axsome Therapeutics' average media sentiment score of 1.01 beat Tango Therapeutics' score of 0.34 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Axsome Therapeutics beats Tango Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Tango Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNGX vs. The Competition

Export

Metric	Tango Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.11B	$3.45B	$6.47B	$12.12B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-34.20	20.09	24.71	24.00
Price / Sales	65.83	188.42	491.85	90.96
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	11.05	8.28	10.82	6.53
Net Income	-$101.59M	$23.85M	$3.56B	$336.99M
7 Day Performance	-11.72%	5.21%	1.67%	-0.22%
1 Month Performance	40.27%	2.19%	0.43%	0.77%
1 Year Performance	433.65%	60.99%	32.84%	31.57%

Tango Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNGX Tango Therapeutics	2.3903 of 5 stars	$28.39 -0.4%	$38.42 +35.3%	+452.3%	$4.11B	$62.38M	N/A	90
VTRS Viatris	3.2816 of 5 stars	$16.14 -1.1%	$17.50 +8.5%	+73.4%	$18.78B	$14.30B	N/A	30,000	News Coverage
GMAB Genmab A/S	4.0239 of 5 stars	$24.46 -0.5%	$37.93 +55.1%	+21.0%	$15.27B	$3.72B	18.55	3,029	Analyst Forecast Options Volume
ASND Ascendis Pharma A/S	4.9172 of 5 stars	$233.74 +4.7%	$295.39 +26.4%	+28.9%	$14.58B	$814.57M	26.96	1,189	Positive News Analyst Downgrade
BBIO BridgeBio Pharma	3.4989 of 5 stars	$67.04 -1.4%	$89.14 +33.0%	+65.2%	$13.13B	$502.08M	N/A	400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNGX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tango Therapeutics (TNGX) Competitors

TNGX vs. VTRS, GMAB, ASND, BBIO, and AXSM

How does Tango Therapeutics compare to Viatris?

Summary

How does Tango Therapeutics compare to Genmab A/S?

Summary

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Tango Therapeutics compare to BridgeBio Pharma?

Summary

How does Tango Therapeutics compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tango Therapeutics (TNGX) Competitors

TNGX vs. VTRS, GMAB, ASND, BBIO, and AXSM

How does Tango Therapeutics compare to Viatris?

Is TNGX or VTRS more profitable?

Which has more risk and volatility, TNGX or VTRS?

Do insiders and institutionals believe in TNGX or VTRS?

Which has better earnings and valuation, TNGX or VTRS?

Do analysts rate TNGX or VTRS?

Does the media prefer TNGX or VTRS?

Summary

How does Tango Therapeutics compare to Genmab A/S?

Which has stronger valuation and earnings, TNGX or GMAB?

Is TNGX or GMAB more profitable?

Which has more risk and volatility, TNGX or GMAB?

Do analysts prefer TNGX or GMAB?

Does the media prefer TNGX or GMAB?

Do institutionals & insiders believe in TNGX or GMAB?

Summary

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Does the media refer more to TNGX or ASND?

Do institutionals and insiders hold more shares of TNGX or ASND?

Which has better valuation and earnings, TNGX or ASND?

Which has more risk & volatility, TNGX or ASND?

Do analysts recommend TNGX or ASND?

Is TNGX or ASND more profitable?

Summary

How does Tango Therapeutics compare to BridgeBio Pharma?

Is BBIO or TNGX more profitable?

Do analysts rate BBIO or TNGX?

Does the media favor BBIO or TNGX?

Which has more risk and volatility, BBIO or TNGX?

Which has better earnings & valuation, BBIO or TNGX?

Do institutionals and insiders hold more shares of BBIO or TNGX?

Summary

How does Tango Therapeutics compare to Axsome Therapeutics?

Do analysts rate AXSM or TNGX?

Which has more volatility & risk, AXSM or TNGX?

Do institutionals and insiders believe in AXSM or TNGX?

Which has preferable valuation and earnings, AXSM or TNGX?

Is AXSM or TNGX more profitable?

Does the media favor AXSM or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools